Valneva Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 0/6
Die Gewinne von Valneva sind jährlich um durchschnittlich 4.6% gestiegen, während die Gewinne der Branche Biotechs jährlich um gewachsen um 23.1% gestiegen sind. Die Umsätze sind jährlich um rückläufig 13.1% gestiegen.
Wichtige Informationen
4.63%
Wachstumsrate der Gewinne
20.65%
EPS-Wachstumsrate
| Biotechs Wachstum der Industrie | 30.80% |
| Wachstumsrate der Einnahmen | -13.06% |
| Eigenkapitalrendite | -194.34% |
| Netto-Marge | -110.29% |
| Nächste Ertragsaktualisierung | 12 Nov 2026 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
Analyseartikel • Aug 16
Valneva SE (EPA:VLA) Just Reported And Analysts Have Been Lifting Their Price Targets
The analysts might have been a bit too bullish on Valneva SE ( EPA:VLA ), given that the company fell short of...
Narrative-Update • Aug 11
VLA: Future Travel Vaccines Will Offset Emerging Demand Headwinds
Analysts have lifted their price target fair value for Valneva from €7.50 to about €11.95, citing updated assumptions for revenue growth, profit margin and future P/E that together support a higher valuation framework. What’s in the News for Valneva Valneva SE scheduled a Board meeting for Jun 25, 2026 to consider appointing independent director Dr. Gerd Zettlmeissl as Chair of the Board of Directors.
Narrative-Update • Jun 27
VLA: Travel Vaccine Headwinds Will Set Up Future Repricing Potential
Analysts have cut their fair value estimate for Valneva from about €6.96 to about €5.23 per share, citing updated assumptions for the discount rate, revenue growth, profit margin, and future P/E levels. What's in the News for Valneva Valneva SE lowered its 2026 earnings guidance and adjusted its product sales guidance to a range of €135 million to €150 million and its total revenue guidance to a range of €145 million to €160 million, citing an emerging adverse trend in travel vaccine uptake across key markets driven by geopolitical factors.Narrative-Update • Jun 13
VLA: Future Travel Vaccines And Lyme Franchise Will Drive Reassessment
Analysts have reduced their price target on Valneva from €10.00 to €7.50, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E multiples as reflected in the latest fair value analysis. What's in the News Valneva revised its 2026 product sales guidance to a range of €135 million to €150 million, with total revenue guidance set at €145 million to €160 million, citing an emerging adverse trend in travel vaccine uptake across key markets driven by geopolitical factors.
Narrative-Update • May 30
VLA: Weaker Travel Vaccine Demand Will Drive Cautious View On Shares
Analysts have slightly reduced their Valneva price target from €2.15 to €2.10, citing revised assumptions around revenue growth, profit margins and a higher implied future P/E multiple in their updated models. What's in the News Valneva adjusted its 2026 guidance, setting product sales in a range of €135 million to €150 million and total revenue guidance at €145 million to €160 million, citing an emerging adverse trend in travel vaccine uptake across key markets linked to geopolitical factors (Corporate Guidance, Lowered).Analyseartikel • May 15
€5.28: That's What Analysts Think Valneva SE (EPA:VLA) Is Worth After Its Latest Results
Valneva SE ( EPA:VLA ) just released its latest first-quarter report and things are not looking great. Statutory...Narrative-Update • May 03
VLA: Lyme Vaccine Progress And Equity Raise Will Shape Balanced Outlook
Analysts have reduced their price target for Valneva from €3.25 to €2.15, citing updated assumptions for discount rates, revenue growth, profit margins and future P/E multiples. What's in the News Valneva filed a follow on equity offering of €37.03 million, covering 15,893,817 ordinary shares at €2.33 per share with attached warrants, under Regulation S (Key Developments).Narrative-Update • Apr 18
VLA: Lyme Vaccine Progress Will Support Earnings Despite Chikungunya Setback
Analysts have kept their Valneva price target steady at €3.25, citing updated assumptions for discount rate, revenue growth, profit margins and future P/E that broadly support the prior valuation level. What's in the News Pfizer and Valneva reported topline Phase 3 VALOR trial results for their 6-valent OspA-based Lyme disease vaccine candidate PF-07307405, with efficacy above 70% in reducing confirmed Lyme cases in two pre specified analyses and no safety concerns identified at the time of analysis.Narrative-Update • Apr 03
VLA: Lyme Vaccine Progress Will Offset Chikungunya Headwinds Over Time
Analysts have raised their Valneva price target from €2.95 to €3.25, citing updated assumptions around revenue growth, profit margins, and a slightly lower future P/E multiple as the main factors behind the change. What's in the News Pfizer and Valneva reported topline Phase 3 VALOR trial data for their investigational 6 valent OspA based Lyme disease vaccine candidate, with efficacy readings in prespecified analyses and Pfizer planning regulatory submissions after reviewing the results and safety profile (Product related announcement).Narrative-Update • Mar 20
VLA: Vaccine Partnerships And Guidance Will Drive Bullish Repricing Potential
Analysts have nudged their price target on Valneva slightly lower to about €6.96 from roughly €6.99, reflecting updated assumptions around discount rates, revenue growth, profit margins and future price-to-earnings levels. What's in the News Elaris FlexCo signed an exclusive global license agreement for Valneva's Clostridioides difficile vaccine candidate VLA84, with plans to use the antigen technology in a next generation program and potential milestone and royalty payments tied to future development, regulatory and commercial outcomes (Key Developments).Narrative-Update • Mar 06
VLA: Future Travel Vaccine Franchise And Real World Data Will Drive Reassessment
Analysts have reaffirmed their €10.00 price target for Valneva, with updated assumptions showing a slightly higher discount rate and profit margin, alongside a lower future P/E, suggesting a more balanced view of risk and earnings potential. What's in the News Valneva issued earnings guidance for 2026, expecting total revenues of €155 million to €170 million, with product sales of €145 million to €160 million.Narrative-Update • Feb 20
VLA: Future Lyme Vaccine Milestones Will Shape Bullish Repricing Potential
Analysts have adjusted their fair value estimate for Valneva from €6.51 to about €6.99. This change reflects updated assumptions on discount rates, revenue growth, profit margins and future P/E multiples.Narrative-Update • Feb 05
VLA: Chikungunya Safety Setbacks Will Weigh On Long Term Earnings Potential
Analysts have reduced their price target on Valneva from €3.25 to €2.95, citing updated assumptions for revenue growth, profit margins and future P/E multiples in their valuation work. What's in the News Valneva and Instituto Butantan launched a Pilot Vaccination Strategy in Brazil using single shot chikungunya vaccine IXCHIQ, aiming for 20% to 40% coverage of adults aged 18 to 59 in ten municipalities as part of post marketing effectiveness and safety studies (Key Developments).Narrative-Update • Jan 22
VLA: Future Vaccine Pipeline Progress Will Support Higher Market Reassessment
Analysts have lifted their fair value estimate for Valneva from €9.50 to €10.00, pointing to adjusted assumptions around discount rates, revenue growth, profit margins and future P/E as the key drivers of the updated price target. What's in the News Valneva decided to voluntarily withdraw the BLA and IND for its chikungunya vaccine IXCHIQ in the US after the FDA suspended the license in August 2025 and later placed the IND on clinical hold following a newly reported foreign serious adverse event that may be plausibly related to vaccination, while causality has not been determined and no active vaccination studies are ongoing (company announcement).Narrative-Update • Jan 07
VLA: Chikungunya Commercial Uncertainty Will Undermine Long Term Earnings Potential
Analysts have adjusted their price targets for Valneva, with updated assumptions that include a discount rate of 6.76%, revenue growth of 9.16%, a profit margin of 26.93% and a forward P/E of 13.87x, reflecting a recalibration of expectations around the company’s risk profile and earnings outlook. What's in the News Valneva and Serum Institute of India agreed to discontinue their license deal for the single shot chikungunya vaccine, with Valneva regaining full rights to manage supply and commercialization in endemic high risk countries within the funding framework agreed with CEPI and the European Union (Client Announcements).Narrative-Update • Dec 14
VLA: Higher Long Term Profit Hopes Will Not Offset Rising Risk
Analysts have trimmed their price target for Valneva from €3.75 to €3.25, reflecting higher perceived risk despite more optimistic long term assumptions for revenue growth and profitability. What's in the News Positive Phase 2 antibody persistence and safety data in 304 children for single shot chikungunya vaccine IXCHIQ, supporting full dose selection and planned Phase 3 development in pediatrics (company announcement) Phase 2 Lyme disease vaccine candidate VLA15 shows strong booster response and favorable safety across age groups, reinforcing partnership with Pfizer ahead of planned 2026 BLA and MAA filings, subject to positive Phase 3 results (company announcement) Strategic reorganization to concentrate French operations in Lyon and close the Nantes site.Analyseartikel • Oct 01
Subdued Growth No Barrier To Valneva SE (EPA:VLA) With Shares Advancing 29%
Despite an already strong run, Valneva SE ( EPA:VLA ) shares have been powering on, with a gain of 29% in the last...Analyseartikel • Sep 10
Is Valneva (EPA:VLA) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Narrative-Update • Aug 24
Rapid Lyme Vaccine Development And Rising Preventative Healthcare Will Shape Future Markets
Valneva's substantial improvement in net profit margin and sharp reduction in future P/E have led to a notable upward revision in the consensus analyst price target from €6.97 to €7.48. What's in the News Health Canada granted marketing authorization for IXCHIQ, Valneva’s single-dose chikungunya vaccine, for individuals aged 12 years and older, supported by robust antibody persistence and safety data.Analyseartikel • Jul 24
Valneva SE's (EPA:VLA) Share Price Boosted 28% But Its Business Prospects Need A Lift Too
Valneva SE ( EPA:VLA ) shareholders are no doubt pleased to see that the share price has bounced 28% in the last month...Neues Narrative • May 14
Upcoming Lyme Vaccine Data Will Unlock Market Opportunities
Potential success of the Lyme disease vaccine could significantly boost future revenue and earnings through strategic regulatory filings and commercialization milestones.Analyseartikel • Feb 20
Valneva SE (EPA:VLA) Analysts Just Slashed Next Year's Revenue Estimates By 13%
Market forces rained on the parade of Valneva SE ( EPA:VLA ) shareholders today, when the analysts downgraded their...Analyseartikel • Feb 06
Valneva SE (EPA:VLA) Stock Catapults 35% Though Its Price And Business Still Lag The Industry
Valneva SE ( EPA:VLA ) shares have had a really impressive month, gaining 35% after a shaky period beforehand. Not all...Analyseartikel • Nov 22
Valneva SE's (EPA:VLA) 25% Dip In Price Shows Sentiment Is Matching Revenues
Unfortunately for some shareholders, the Valneva SE ( EPA:VLA ) share price has dived 25% in the last thirty days...Analyseartikel • Nov 10
€6.97: That's What Analysts Think Valneva SE (EPA:VLA) Is Worth After Its Latest Results
Valneva SE ( EPA:VLA ) just released its latest quarterly results and things are looking bullish. Results overall were...Aufschlüsselung der Einnahmen und Ausgaben
Aufschlüsselung der Einnahmen und Ausgaben
Wie Valneva Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Gewinn | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 30 Jun 26 | 143 | -158 | 64 | 0 |
| 31 Mar 26 | 156 | -138 | 70 | 0 |
| 31 Dec 25 | 175 | -115 | 75 | 0 |
| 30 Sep 25 | 180 | -102 | 85 | 0 |
| 30 Jun 25 | 196 | -67 | 88 | 0 |
| 31 Mar 25 | 186 | -80 | 91 | 0 |
| 31 Dec 24 | 170 | -12 | 95 | 0 |
| 30 Sep 24 | 159 | -7 | 96 | 0 |
| 30 Jun 24 | 156 | -32 | 100 | 0 |
| 31 Mar 24 | 153 | -24 | 101 | 0 |
| 31 Dec 23 | 154 | -101 | 97 | 0 |
| 30 Sep 23 | 223 | -113 | 90 | 0 |
| 30 Jun 23 | 426 | -7 | 77 | -52 |
| 31 Mar 23 | 373 | -135 | 69 | 0 |
| 31 Dec 22 | 361 | -143 | 58 | 0 |
| 30 Sep 22 | 439 | 73 | 61 | 0 |
| 30 Jun 22 | 304 | -159 | 65 | 52 |
| 31 Mar 22 | 347 | -72 | 64 | 0 |
| 31 Dec 21 | 348 | -73 | 71 | 0 |
| 30 Sep 21 | 121 | -248 | 60 | 0 |
| 30 Jun 21 | 110 | -125 | 56 | 0 |
| 31 Mar 21 | 98 | -91 | 50 | 0 |
| 31 Dec 20 | 110 | -64 | 46 | 0 |
| 30 Sep 20 | 104 | -62 | 46 | 0 |
| 30 Jun 20 | 120 | -25 | 43 | 0 |
| 31 Mar 20 | 127 | -8 | 44 | 0 |
| 31 Dec 19 | 126 | -2 | 43 | 0 |
| 30 Sep 19 | 116 | 4 | 40 | 0 |
| 30 Jun 19 | 109 | 1 | 39 | 0 |
| 31 Mar 19 | 116 | 7 | 38 | 0 |
| 31 Dec 18 | 113 | 3 | 38 | 0 |
| 30 Sep 18 | 107 | -7 | 38 | 0 |
| 30 Jun 18 | 110 | -7 | 38 | 0 |
| 31 Mar 18 | 108 | -8 | 35 | 0 |
| 31 Dec 17 | 105 | -11 | 33 | 0 |
| 30 Sep 17 | 103 | -11 | 33 | 0 |
| 30 Jun 17 | 100 | -14 | 32 | 0 |
| 31 Mar 17 | 102 | -46 | 32 | 0 |
| 31 Dec 16 | 98 | -49 | 31 | 0 |
| 30 Sep 16 | 93 | -63 | 29 | 0 |
| 30 Jun 16 | 96 | -61 | 28 | 0 |
| 31 Mar 16 | 89 | -35 | 27 | 0 |
| 31 Dec 15 | 83 | -21 | 24 | 0 |
| 30 Sep 15 | 74 | -16 | 20 | 0 |
Qualität der Erträge: VLA ist derzeit unrentabel.
Wachsende Gewinnspanne: VLA ist derzeit unrentabel.
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: VLA ist unrentabel, hat aber in den letzten 5 Jahren die Verluste mit einer Rate von 4.6% pro Jahr reduziert.
Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von VLA verglichen werden, da das Unternehmen derzeit nicht profitabel ist.
Erträge im Vergleich zur Industrie: VLA ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Biotechs (8.4%) erschwert.
Eigenkapitalrendite
Hohe Eigenkapitalrendite: VLA hat eine negative Eigenkapitalrendite (-194.34%), da es derzeit unrentabel ist.
Kapitalrendite
Rendite auf das eingesetzte Kapital
Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/08/24 19:23 |
| Aktienkurs zum Tagesende | 2026/08/24 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Valneva SE wird von 16 Analysten beobachtet. 10 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Vladimira Urbankova | Erste Group Bank AG |
| Simon Scholes | First Berlin Equity Research GmbH |
| Rajan Sharma | Goldman Sachs |